Erlotinib monotherapy for the maintenance treatment of non-small-cell lung cancer after previous platinum containing chemotherapy.
| Status: |
In progress |
| Expected date of issue: |
August 2010 |
| Referral date: |
November 2008 |
| Wave: |
19 |
| Process: |
STA |
| Topic area:
|
NICE project team
| Executive Lead: |
Peter Littlejohns
|
| Technical Lead: |
Sally Gallaugher
|
| Communications manager: |
Alice Law
|
| Project manager: |
Kate Moore
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
19 January 2010 |
| 1st appraisal committee meeting: |
27 April 2010 |
Consultees and Commentators
|
| Consultees |
Commentators (no right to submit or appeal) |
|
Manufacturers/sponsors
Patient/carer groups
- Macmillan Cancer Support
- Roy Castle Lung Cancer Foundation
Professional groups
- British Thoracic Society
- National Lung Cancer Forum for Nurses
- Royal College of Nursing
- Royal College of Physicians’ Intercollegiate Lung Cancer Group
- United Kingdom Oncology Nursing Society
Others
- Cornwall and the Isles of Scilly PCT
- Department of Health
- Dudley PCT
- Welsh Assembly Government
|
General
- NHS Quality Improvement Scotland
Comparator manufacturers
- Eli Lilly & Co. (pemetrexed)
Relevant research groups
- British Thoracic Oncology Group
Evidence Review Group
- Liverpool Reviews and Implementation Group (LRIG)
- National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups
- National Collaborating Centre for Cancer
Associated Public Health Groups
|
|
Project history
| Date |
Update |
| 15 May 2009 |
The above appraisal has been rescheduled to align with latest regulatory expectations. We expect a new submission date in November 2009. |
|
Key documents
|
|
|
This page was last updated: 19 January 2010 |
